Repligen (RGEN) Reports In-Line Q4 EPS, Offers Guidance
Get Alerts RGEN Hot Sheet
Price: $168.53 +0.55%
Revenue Growth %: +9.4%
Financial Fact:
Cost of product revenue: 11.24M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +9.4%
Financial Fact:
Cost of product revenue: 11.24M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Repligen (NASDAQ: RGEN) reported Q4 EPS of $0.21, in-line with the analyst estimate of $0.21. Revenue for the quarter came in at $51.9 million versus the consensus estimate of $50.4 million.
GUIDANCE:
Repligen sees FY2019 EPS of $0.81-$0.86, versus the consensus of $0.85. Repligen sees FY2019 revenue of $218-225 million, versus the consensus of $217.25 million.
For earnings history and earnings-related data on Repligen (RGEN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Casey's General Stores (CASY) Tops Q1 EPS by 69c
- Braze stock tumbles 10% on weak third quarter EPS guidance
- HSBC Raises S&P500 Target to 8,100
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share